Alafair Biosciences develops cross-linked polysaccharide hydrogel films to address the post-surgical complication of unwanted soft tissue attachments, or tethering between opposing tissue surfaces. Adhesion care is a major reason for hospital readmission. Many surgeons forego utilizing currently available products due to their poor handling and/or efficacy.
Unwanted postoperative scars formed by the natural injury response often tether tissues normally separated, causing pain, infection, loss of function, or re-injury. The problem of undesirable soft tissue attachments, observed following any surgical procedure, bears a healthcare burden of $3.45 billion in the US, annually. Current prevention products have poor handling qualities, thus multiple product units are wasted during use due to difficulty of application. This difficulty in surgical placement results in significant underutilization of preventive barriers, leaving surgeons wanting a better solution.
Alafair has solved the problems which plague our target market, through the development of conformable, malleable, and easily applied solutions. These unique medical products utilize a novel hydrogel platform. The foundation of the product pipeline is an interpenetrating microscopic network providing:
- Robust handling characteristics
- Significant hydrophilicity
- Tunable degradation rates.
The follow-on product pipeline includes membrane, bilayer, and injectable gel solutions for applications in scar prevention, wound care, and tissue reconstruction. Alafair’s initial product is a film that exhibits superior handling and mechanical properties as compared to competing products, with preliminary in vivo studies showing promising soft tissue reconstruction and degradation results.
The patent-pending technology was developed at UT Austin in the laboratory of Dr. Christine Schmidt.